Advitech is a Canadian-based life sciences and technology company that has been active in the industry since 1997. The company specializes in discovering and commercializing patented, scientifically supported natural health products. Advitech's focus lies in addressing immune system disorders, such as psoriasis and inflammatory bowel disease, with effective and safe products. Their flagship offering, Dermylex®, is designed for treating mild to moderate psoriasis. Moreover, the company has embarked on a research program to explore new applications in wound healing, utilizing the technological platforms XP-828L and IM.
The latest funding round for Advitech occurred on 21 July 2010, where Avrio Capital invested $1.44M. Advitech operates in the industries of Biotechnology and Platforms.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $1.44M | 1 |
|
21 Jul 2010 |
| Venture Round | $2.52M | 3 |
|
26 Nov 2009 |
No recent news or press coverage available for Advitech.
We care about your data, and we'd love to use cookies make your experience better.
